Pub Date : 2025-10-01DOI: 10.1016/j.alit.2025.08.004
Kairi Furui, Koh Sakano, Masahito Ohue
Protein language models (pLMs) are rapidly emerging as revolutionary artificial intelligence technologies that bring transformative changes to drug discovery and therapeutic research. pLMs acquire rich representational capabilities from large-scale sequence datasets, enabling the solution of various biological problems that were difficult with conventional methods. In this review, we provide a comprehensive overview of various pLMs and their implementations, exploring their potential utility in drug discovery and therapeutic research. First, we systematically classify pLMs based on their architectures and information sources while discussing their development to the present. We also explain recent trends in multimodal approaches that integrate co-evolutionary information, structural information, and functional information, as well as domain-specific models specialized for particular domains such as antibodies and T-cell receptors. We then provide a comprehensive overview of various therapeutic applications of pLMs, including mutation effect prediction, function prediction, and structure prediction. Finally, we discuss future prospects of pLMs toward therapeutic applications and challenges for transforming them into technologies that contribute to actual diseases.
{"title":"Predictive and therapeutic applications of protein language models","authors":"Kairi Furui, Koh Sakano, Masahito Ohue","doi":"10.1016/j.alit.2025.08.004","DOIUrl":"10.1016/j.alit.2025.08.004","url":null,"abstract":"<div><div>Protein language models (pLMs) are rapidly emerging as revolutionary artificial intelligence technologies that bring transformative changes to drug discovery and therapeutic research. pLMs acquire rich representational capabilities from large-scale sequence datasets, enabling the solution of various biological problems that were difficult with conventional methods. In this review, we provide a comprehensive overview of various pLMs and their implementations, exploring their potential utility in drug discovery and therapeutic research. First, we systematically classify pLMs based on their architectures and information sources while discussing their development to the present. We also explain recent trends in multimodal approaches that integrate co-evolutionary information, structural information, and functional information, as well as domain-specific models specialized for particular domains such as antibodies and T-cell receptors. We then provide a comprehensive overview of various therapeutic applications of pLMs, including mutation effect prediction, function prediction, and structure prediction. Finally, we discuss future prospects of pLMs toward therapeutic applications and challenges for transforming them into technologies that contribute to actual diseases.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 534-548"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145087922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1016/j.alit.2025.08.005
Teppei Shimamura
Single-cell RNA sequencing (scRNA-seq) has revolutionized biology through high-throughput quantification of gene expression at individual cell resolution. However, standard scRNA-seq provides only static cellular snapshots, obscuring dynamic processes that unfold temporally, such as differentiation, reprogramming, and disease progression. RNA Velocity, introduced in 2018, offers a groundbreaking solution. By leveraging unspliced pre-mRNA and spliced mRNA information, RNA Velocity models infer instantaneous gene expression change rates and effectively predict future transcriptional states over hour-long timescales. This review charts the evolution of this powerful concept, beginning with foundational principles and mathematical models of transcriptional dynamics. We explore Velocyto’s pioneering implementation, discuss successes and limitations, and then examine second-generation advanced computational tools that generalize the framework, including scVelo, dynamo, and CellRank. A dedicated section highlights growing applications in allergy and immunology research, where these methods reveal novel disease mechanisms in asthma, atopic dermatitis, and chronic inflammation by analyzing immune cell differentiation and state transitions. We explored modern frontiers, including RNA Velocity integration with spatial and multimodal data, and the latest deep learning-based methods. Finally, we addressed the current challenges and remaining limitations of RNA Velocity analysis, offering insights into best practices and future directions. Throughout, we emphasize applications to allergic and immune-mediated diseases—including asthma, atopic dermatitis, and prurigo nodularis—to guide researchers and clinicians in allergy and immunology. RNA Velocity is becoming indispensable for navigating the complex, dynamic cellular world and transforming our understanding of temporal biological processes from static observations to predictive, dynamic insights that illuminate cellular fate decisions and disease mechanisms.
{"title":"RNA velocity and beyond: Current advances in modeling single-cell transcriptional dynamics","authors":"Teppei Shimamura","doi":"10.1016/j.alit.2025.08.005","DOIUrl":"10.1016/j.alit.2025.08.005","url":null,"abstract":"<div><div>Single-cell RNA sequencing (scRNA-seq) has revolutionized biology through high-throughput quantification of gene expression at individual cell resolution. However, standard scRNA-seq provides only static cellular snapshots, obscuring dynamic processes that unfold temporally, such as differentiation, reprogramming, and disease progression. RNA Velocity, introduced in 2018, offers a groundbreaking solution. By leveraging unspliced pre-mRNA and spliced mRNA information, RNA Velocity models infer instantaneous gene expression change rates and effectively predict future transcriptional states over hour-long timescales. This review charts the evolution of this powerful concept, beginning with foundational principles and mathematical models of transcriptional dynamics. We explore Velocyto’s pioneering implementation, discuss successes and limitations, and then examine second-generation advanced computational tools that generalize the framework, including scVelo, dynamo, and CellRank. A dedicated section highlights growing applications in allergy and immunology research, where these methods reveal novel disease mechanisms in asthma, atopic dermatitis, and chronic inflammation by analyzing immune cell differentiation and state transitions. We explored modern frontiers, including RNA Velocity integration with spatial and multimodal data, and the latest deep learning-based methods. Finally, we addressed the current challenges and remaining limitations of RNA Velocity analysis, offering insights into best practices and future directions. Throughout, we emphasize applications to allergic and immune-mediated diseases—including asthma, atopic dermatitis, and prurigo nodularis—to guide researchers and clinicians in allergy and immunology. RNA Velocity is becoming indispensable for navigating the complex, dynamic cellular world and transforming our understanding of temporal biological processes from static observations to predictive, dynamic insights that illuminate cellular fate decisions and disease mechanisms.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 4","pages":"Pages 525-533"},"PeriodicalIF":6.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-10DOI: 10.1016/j.alit.2025.05.008
Yuko Watanabe , Natsumi Hama
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious mucocutaneous disorders primarily caused by medications. Despite their low incidence, both conditions remain associated with high mortality and significant long-term complications. Recent studies have advanced the understanding of their pathogenesis, including the roles of neutrophil extracellular traps and several cell death pathways. However, reliable biomarkers for early diagnosis are lacking, and no internationally standardized diagnostic criteria have been established.
To address these gaps, new diagnostic frameworks have been proposed that incorporate conventional cutaneous and mucosal findings with mandatory histopathological confirmation. These are expected to enhance diagnostic precision and facilitate global comparability. The increasing incidence of SJS/TEN-like reactions associated with immune checkpoint inhibitors and molecular targeted therapies further highlights the importance of accurate histopathological differentiation.
Prognostic tools are essential for therapeutic planning. Although the Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) score remains widely used, newer systems offer improved risk stratification and practical utility in diverse clinical settings.
However, the optimal use of immunomodulatory therapies remains uncertain owing to limited consensus and evidence. Corticosteroids continue to serve as first-line treatment, but more selective agents are gaining attention for their potential efficacy and reduced toxicity.
This review summarizes recent progress in SJS/TEN diagnosis, severity assessment, and management. It discusses the utility and limitations of novel scoring systems and emerging therapies while highlighting persistent challenges, including high mortality, regional practice variation, and delayed standardization. International collaboration and high-quality evidence generation remain essential for improving patient outcomes.
{"title":"Recent advances in the diagnosis and treatment of Stevens–Johnson syndrome/toxic epidermal necrolysis","authors":"Yuko Watanabe , Natsumi Hama","doi":"10.1016/j.alit.2025.05.008","DOIUrl":"10.1016/j.alit.2025.05.008","url":null,"abstract":"<div><div>Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious mucocutaneous disorders primarily caused by medications. Despite their low incidence, both conditions remain associated with high mortality and significant long-term complications. Recent studies have advanced the understanding of their pathogenesis, including the roles of neutrophil extracellular traps and several cell death pathways. However, reliable biomarkers for early diagnosis are lacking, and no internationally standardized diagnostic criteria have been established.</div><div>To address these gaps, new diagnostic frameworks have been proposed that incorporate conventional cutaneous and mucosal findings with mandatory histopathological confirmation. These are expected to enhance diagnostic precision and facilitate global comparability. The increasing incidence of SJS/TEN-like reactions associated with immune checkpoint inhibitors and molecular targeted therapies further highlights the importance of accurate histopathological differentiation.</div><div>Prognostic tools are essential for therapeutic planning. Although the Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) score remains widely used, newer systems offer improved risk stratification and practical utility in diverse clinical settings.</div><div>However, the optimal use of immunomodulatory therapies remains uncertain owing to limited consensus and evidence. Corticosteroids continue to serve as first-line treatment, but more selective agents are gaining attention for their potential efficacy and reduced toxicity.</div><div>This review summarizes recent progress in SJS/TEN diagnosis, severity assessment, and management. It discusses the utility and limitations of novel scoring systems and emerging therapies while highlighting persistent challenges, including high mortality, regional practice variation, and delayed standardization. International collaboration and high-quality evidence generation remain essential for improving patient outcomes.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 345-355"},"PeriodicalIF":6.2,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-10DOI: 10.1016/j.alit.2025.05.003
Chie Sotozono, Mayumi Ueta
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute inflammatory disorders that affect the skin and mucous membranes, and in 40–84 % of SJS/TEN cases, the ocular complications that are often overlooked due to severe systemic symptoms. Specific ocular findings at the acute-phase include conjunctival hyperemia, pseudomembrane formation, and epithelial defects, and severe acute-phase ocular involvement strongly correlates with long-term visual impairment. Thus, it is vital to diagnose ocular involvement early at the acute stage and suppress inflammation on the ocular surface to protect corneal epithelial stem cells. As outlined in the official Japanese treatment guidelines for SJS/TEN cases with ocular involvement, corticosteroid pulse therapy and topical application of 0.1 % betamethasone eye-drops within four days of disease onset significantly reduces ocular sequelae. Early intervention with amniotic membrane transplantation helps reduce scarring and potential loss of vision. As for genetic-related factors, NSAIDs (nonsteroidal anti-inflammatory drugs) and cold medications are major triggers for SJS/TEN with severe ocular complications, with genetic predispositions involving TLR3 and prostaglandin E receptor 3 (subtype EP3) contributing to disease susceptibility. These genetic–environment interactions influence disease onset and progression. At chronic phase, severe dry eye and visual impairment are major long-term sequelae, and both surgical and non-surgical interventions have been applied to obtain favorable long-term treatment outcomes. In summary, early ophthalmic intervention is critical in preventing SJS/TEN-related ocular sequelae, and further research into genetic and immunological mechanisms is essential for better diagnosis and treatment.
{"title":"Updates on the ocular manifestations and treatment of SJS/TEN","authors":"Chie Sotozono, Mayumi Ueta","doi":"10.1016/j.alit.2025.05.003","DOIUrl":"10.1016/j.alit.2025.05.003","url":null,"abstract":"<div><div>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute inflammatory disorders that affect the skin and mucous membranes, and in 40–84 % of SJS/TEN cases, the ocular complications that are often overlooked due to severe systemic symptoms. Specific ocular findings at the acute-phase include conjunctival hyperemia, pseudomembrane formation, and epithelial defects, and severe acute-phase ocular involvement strongly correlates with long-term visual impairment. Thus, it is vital to diagnose ocular involvement early at the acute stage and suppress inflammation on the ocular surface to protect corneal epithelial stem cells. As outlined in the official Japanese treatment guidelines for SJS/TEN cases with ocular involvement, corticosteroid pulse therapy and topical application of 0.1 % betamethasone eye-drops within four days of disease onset significantly reduces ocular sequelae. Early intervention with amniotic membrane transplantation helps reduce scarring and potential loss of vision. As for genetic-related factors, NSAIDs (nonsteroidal anti-inflammatory drugs) and cold medications are major triggers for SJS/TEN with severe ocular complications, with genetic predispositions involving TLR3 and prostaglandin E receptor 3 (subtype EP3) contributing to disease susceptibility. These genetic–environment interactions influence disease onset and progression. At chronic phase, severe dry eye and visual impairment are major long-term sequelae, and both surgical and non-surgical interventions have been applied to obtain favorable long-term treatment outcomes. In summary, early ophthalmic intervention is critical in preventing SJS/TEN-related ocular sequelae, and further research into genetic and immunological mechanisms is essential for better diagnosis and treatment.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 356-360"},"PeriodicalIF":6.2,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-04DOI: 10.1016/j.alit.2025.05.002
Joy Justice , Eric Mukherjee , Michelle Martin-Pozo , Elizabeth Phillips
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions across a spectrum of severity characterized by widespread epidermal detachment and keratinocyte apoptosis. SJS/TEN develops due to a complex immunologic response after exposure to an associated drug antigen and/or its metabolite, and it results in significant morbidity and mortality. Complex immune mechanisms contribute to keratinocyte death. Drug-induced SJS/TEN has been shown to be strongly HLA class I restricted which has contributed to our understanding of mechanisms and has the potential to shape prevention and diagnosis. There is currently no evidence-based treatment outside of aggressive supportive care, and understanding the complete immunopathogenesis of SJS/TEN will be key for the development of efficacious and safe treatments that significantly reduce morbidity and mortality. This article focuses on what is new in the pathogenesis of SJS/TEN, including recent research on the mechanisms of T-cell activation, apoptotic and necroptotic mediators, other related molecules, genetic associations, and possible targeted treatment options.
{"title":"Updates in the pathogenesis of SJS/TEN","authors":"Joy Justice , Eric Mukherjee , Michelle Martin-Pozo , Elizabeth Phillips","doi":"10.1016/j.alit.2025.05.002","DOIUrl":"10.1016/j.alit.2025.05.002","url":null,"abstract":"<div><div>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions across a spectrum of severity characterized by widespread epidermal detachment and keratinocyte apoptosis. SJS/TEN develops due to a complex immunologic response after exposure to an associated drug antigen and/or its metabolite, and it results in significant morbidity and mortality. Complex immune mechanisms contribute to keratinocyte death. Drug-induced SJS/TEN has been shown to be strongly HLA class I restricted which has contributed to our understanding of mechanisms and has the potential to shape prevention and diagnosis. There is currently no evidence-based treatment outside of aggressive supportive care, and understanding the complete immunopathogenesis of SJS/TEN will be key for the development of efficacious and safe treatments that significantly reduce morbidity and mortality. This article focuses on what is new in the pathogenesis of SJS/TEN, including recent research on the mechanisms of T-cell activation, apoptotic and necroptotic mediators, other related molecules, genetic associations, and possible targeted treatment options.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 361-371"},"PeriodicalIF":6.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-23DOI: 10.1016/j.alit.2025.03.006
Donyea L. Moore , Evan A. Patel , Bobby A. Tajudeen , Pete S. Batra , Mahboobeh Mahdavinia
{"title":"Examining effects of race and chronic rhinosinusitis on asthma; more evidence for unified-airway diseases","authors":"Donyea L. Moore , Evan A. Patel , Bobby A. Tajudeen , Pete S. Batra , Mahboobeh Mahdavinia","doi":"10.1016/j.alit.2025.03.006","DOIUrl":"10.1016/j.alit.2025.03.006","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 488-490"},"PeriodicalIF":6.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-17DOI: 10.1016/j.alit.2025.03.007
Yoshiko Mizukawa, Tetsuo Shiohara
Drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug reaction characterized by a range of clinical manifestations. These range from mild cases resolving upon cessation of the causative drug to severe cases involving complex disease progression and potential fatality. A hallmark of DIHS/DRESS is the sequential reactivation of herpesviruses, particularly human herpesvirus 6 (HHV-6), during the disease course, contributing to recurrent symptoms. Viral reactivation can lead to critical complications, including infectious DIHS/DRESS-associated complications (iDACs) and autoimmune sequelae (aDACs). Managing DIHS/DRESS remains challenging due to its complexity, requiring precise prediction and tailored treatment strategies. Recent studies suggest that early-stage classification using the DIHS/DRESS Severity (DDS) score may help identify refractory cases, including DACs. Furthermore, early intervention with anti-cytomegalovirus (anti-CMV) therapy can mitigate iDACs caused by CMV reactivation, preventing progression to severe CMV-related diseases. Long-term follow-up is crucial, as aDACs can manifest even 3 years postonset. Serial monitoring is recommended, particularly in patients treated with intravenous immunoglobulin or corticosteroid pulse therapy, which are recognized risk factors for aDAC development. This review highlights DIHS/DRESS management strategies, focusing on its clinical features, the role of viral reactivation, and therapeutic interventions.
{"title":"Recent advances in the diagnosis and treatment of DIHS/DRESS in 2025","authors":"Yoshiko Mizukawa, Tetsuo Shiohara","doi":"10.1016/j.alit.2025.03.007","DOIUrl":"10.1016/j.alit.2025.03.007","url":null,"abstract":"<div><div>Drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug reaction characterized by a range of clinical manifestations. These range from mild cases resolving upon cessation of the causative drug to severe cases involving complex disease progression and potential fatality. A hallmark of DIHS/DRESS is the sequential reactivation of herpesviruses, particularly human herpesvirus 6 (HHV-6), during the disease course, contributing to recurrent symptoms. Viral reactivation can lead to critical complications, including infectious DIHS/DRESS-associated complications (iDACs) and autoimmune sequelae (aDACs). Managing DIHS/DRESS remains challenging due to its complexity, requiring precise prediction and tailored treatment strategies. Recent studies suggest that early-stage classification using the DIHS/DRESS Severity (DDS) score may help identify refractory cases, including DACs. Furthermore, early intervention with anti-cytomegalovirus (anti-CMV) therapy can mitigate iDACs caused by CMV reactivation, preventing progression to severe CMV-related diseases. Long-term follow-up is crucial, as aDACs can manifest even 3 years postonset. Serial monitoring is recommended, particularly in patients treated with intravenous immunoglobulin or corticosteroid pulse therapy, which are recognized risk factors for aDAC development. This review highlights DIHS/DRESS management strategies, focusing on its clinical features, the role of viral reactivation, and therapeutic interventions.</div></div>","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 372-379"},"PeriodicalIF":6.2,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-17DOI: 10.1016/j.alit.2025.04.001
Daigo Kato , Takako Miyamae , Yuzaburo Inoue
{"title":"Medical treatment recipient ratio for metal allergy among Japanese children and adolescents: A retrospective cohort study using health insurance claims data (2016–2020)","authors":"Daigo Kato , Takako Miyamae , Yuzaburo Inoue","doi":"10.1016/j.alit.2025.04.001","DOIUrl":"10.1016/j.alit.2025.04.001","url":null,"abstract":"","PeriodicalId":48861,"journal":{"name":"Allergology International","volume":"74 3","pages":"Pages 491-493"},"PeriodicalIF":6.2,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号